Login / Signup

Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial.

Alberto MartiniJohn PfailFrancesco MontorsiMatthew D GalskyWilliam K Oh
Published in: Prostate cancer and prostatic diseases (2020)
Progression within 6 months following combination therapy emerged as the best surrogate for OS.
Keyphrases
  • combination therapy
  • prostate cancer
  • radical prostatectomy
  • study protocol
  • phase iii
  • clinical trial
  • phase ii
  • free survival
  • randomized controlled trial
  • open label